Nalbuphine ER Tablets

Drug identity checked against registry records

Also recorded as NAL ER Tablets

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
PRISM Study-Pruritus Relief Through Itch Scratch ModulationNCT03497975Trevi TherapeuticsPhase 2, Phase 3Completed2022-05-10Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.